Switch View
© PR Newswire
29.10.2025
ISIN: IE00BGH1M568
Perrigo Company PLC
PRGO
LISTED
NYSE
Perrigo Announces Quarterly Dividend
News Preview
DUBLIN, Oct. 29, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of consumer health products, today announced that its Board of Directors declared a quarterly dividend of $0.290 per share, payable on December 16, 2025, to shareholders of record on November 28, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2025
ISIN: US88165K1016
Tevogen Bio Holdings Inc.
TVGN
LISTED
NASDAQ
Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress
News Preview
WARREN, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), in ongoing community, industry, and academic engagements, has continued to underscore its biopharma model centered on sustainability and patient affordability, highlighting the Company’s significant progress toward making precision m...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2025
ISIN: US44975P1030
I-Mab
IMAB
LISTED
NASDAQ
I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform
News Preview
New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide
Strategy centers on broadening access to global capital and innovation through a planned Hong Kong initial public offering (IPO), and holding dual...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© ACCESSWIRE
29.10.2025
ISIN: CA0717341071
Bausch Health Companies Inc
BHC
LISTED
TSX
Bausch Health Announces Third Quarter 2025 Results
News Preview
Third Quarter Consolidated Revenues of $2.68 billion, up 7% on a Reported basis and 5% on an Organic (non-GAAP)1 basis over the prior year periodGAAP Net Income Attributable to Bausch Health of $179 million and GAAP Net Income of $181 millionConsolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP)1 of $986 million, including an $81 mil...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
29.10.2025
ISIN: US60855R1005
Molina Healthcare Inc
MOH
LISTED
NYSE
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Molina Healthcare
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Molina To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $75,000 in Molina between February 5...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2025
ISIN: US5324571083
Eli Lilly and Co
LLY
LISTED
NYSE
Lilly announces more than $1.2 billion investment in Puerto Rico facility to boost oral medicine manufacturing capacity in the United States
News Preview
Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs
INDIANAPOLIS, Oct. 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today a planned investment of more than $1.2 billion to expand and modernize its Lilly del Ca...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of LifeMD
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In LifeMD To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $75,000 in LifeMD between May 7, 202...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Cytokinetics To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $75,000 in Cytokinetics betwee...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2025
ISIN: US1920051067
Codexis Inc
CDXS
LISTED
NASDAQ
Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's ECO Synthesis® Manufacturing Platform for Therapeutic siRNA Manufacturing
News Preview
REDWOOD CITY, Calif., Oct. 29, 2025 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, and Nitto Denko Avecia, Inc. a leading contract development and manufacturing organization (CDMO) specializing in oligonucleotide thera...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2025
ISIN: US1920051067
Codexis Inc
CDXS
LISTED
NASDAQ
Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's ECO Synthesis® Manufacturing Platform for Therapeutic siRNA Manufacturing
News Preview
REDWOOD CITY, Calif., Oct. 29, 2025 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, and Nitto Denko Avecia, Inc. a leading contract development and manufacturing organization (CDMO) specializing in oligonucleotide thera...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2025
ISIN: GB00BDFBVT43
Oxford Biomedica PLC
OXB
LISTED
LSE
OXB honoured at 2025 CDMO Leadership Awards Europe in ‘Cell & Gene Therapy’ category
News Preview
Oxford, UK – 29 October 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised as a Champion in the ‘Cell & Gene Therapy’ category at the 2025 CDMO Leadership Awards Europe in Frankfurt. The prestigious Champion title is awarded to the highest-scoring CDMO in each category, b...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2025
ISIN: US09061G1013
BioMarin Pharmaceutical Inc
BMRN
LISTED
NASDAQ
FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria
News Preview
Application based on positive results from Phase 3 PEGASUS study, which demonstrated statistically significant blood phenylalanine (Phe) lowering compared to diet alone
FDA PDUFA target action date of Feb. 28, 2026...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
29.10.2025
ISIN: US88025U1097
10X Genomics Inc
TXG
LISTED
NASDAQ
10x Genomics Launches the Next Generation of Chromium Flex to Empower Scientists to Massively Scale Single Cell Research
News Preview
New plate-based multiplexing unlocks ultra high-sample and cell-throughput single cell analysis to empower a broad range of studies
PLEASANTON, Calif., Oct. 29, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology,...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2025
ISIN: US09075D1028
BioXyTran, Inc.
BIXT
LISTED
OTC
Bioxytran Completes Randomized Clinical Trial For its Broad-Spectrum Antiviral Drug
News Preview
BOSTON, MASSACHUSETTS, Oct. 29, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company pioneering innovative therapies for viral diseases, is pleased to announce the successful completion of its second randomized double-blind, placebo-controlled clinical trial for its leading broad-spectrum...
Themefolio
Profiler
Peergroup
© BusinessWire
29.10.2025
ISIN: US8753722037
Tandem Diabetes Care Inc
TNDM
LISTED
NASDAQ
t:slim X2™ Insulin Pump Now Available with Abbott’s FreeStyle Libre® 3 Plus Sensor in the United States
News Preview
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced that the t:slim X2 insulin pump, featuring Control-IQ+ automated insulin delivery (AID) technology, is now available with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensor integration in the United States.* This...
Themefolio
Profiler
Peergroup
© BusinessWire
29.10.2025
ISIN: US98978V1035
Zoetis Inc
ZTS
LISTED
NYSE
Zoetis Receives European Commission Marketing Authorization for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats
News Preview
Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Portela® (relfovetmab), making it the first monoclonal antibody (mAb) therapy with a three-month dosing interval approved for the alleviation of pain associated with osteoarthritis (OA) in cats.
Designed to provide three months of OA pain...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2025
ISIN: US0327241065
AnaptysBio Inc
ANAB
LISTED
NASDAQ
Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation
News Preview
SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced late-breaking data from the robust, global 424-patient Phase 2b trial of rosnilimab, a selective and potent pathogenic T cell depleter, in rheumatoid arthrit...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2025
ISIN: US00287Y1091
AbbVie Inc
ABBV
LISTED
EURONEXT
AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo
News Preview
In two replicate Phase 3 studies, upadacitinib (RINVOQ
®
) achieved the co-primary endpoints of 50% reduction in Total Vitiligo Area Scoring Index (T-VASI 50) fr...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2025
ISIN: US7665596034
Rigel Pharmaceuticals, Inc.
RIGL
LISTED
NASDAQ
Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update
News Preview
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2025 financial results after market close on Tuesday, November 4, 2025. Rigel senior management will follow the announcement with a live conference call and w...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2025
ISIN: US4781601046
Johnson & Johnson
JNJ
LISTED
NYSE
Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting
News Preview
The EPIC study will evaluate treatment with IMAAVY™ versus efgartigimod in adults with gMG and will include a treatment-switch arm
The Company also announced new data from the pivotal Vibrance-MG study in which pediatric patients receiving treatment with IMAAVY...
Themefolio
Profiler
Peergroup
© BusinessWire
29.10.2025
ISIN: US1241551027
Butterfly Network Inc
BFLY
LISTED
NYSE
Butterfly Network to Participate at UBS Global Healthcare Conference 2025
News Preview
Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced that Joseph DeVivo, President, Chief Executive Officer & Chairman and Megan Carlson, Senior Vice President & Interim Chief Financial Officer will participate in a firesi...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2025
ISIN: US70387R4039
PAVmed, Inc.
PAVM
LISTED
NASDAQ
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025
News Preview
Conference Call and Webcast at 8:30 AM Eastern Time
NEW YORK, Oct. 29, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq:...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2025
ISIN: US44975P1030
I-Mab
IMAB
LISTED
NASDAQ
I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform
News Preview
ROCKVILLE, Md., Oct. 29, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NovaBridge or the Company) today announced that it has changed its corporate name from I-Mab to NovaBridge Biosciences. The change was overwhelmingly approved by shareholders at the Company’s Extraordinary General Meeting held on October 24, 2025, and by the Company’s Board...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2025
ISIN: US55279B3015
Lite Strategy, Inc.
LITS
LISTED
NASDAQ
Lite Strategy Announces $25M Share Repurchase Program, Signaling Shift From Initial Litecoin Accumulation to Active Capital Market Operations
News Preview
Lite Strategy Announces $25M Share Repurchase Program, Shifting From Initial Litecoin Accumulation to Active Capital Market Operations...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2025
ISIN: US9026731029
UFP Technologies Inc
UFPT
LISTED
NASDAQ
UFP Technologies to Report Third Quarter 2025 Financial Results on November 3, 2025
News Preview
Conference Call Scheduled for November 4th at 8:30 AM ET Conference Call Scheduled for November 4th at 8:30 AM ET...
Themefolio
Profiler
Peergroup
© Newsfile
29.10.2025
ISIN: US29415V1098
Envoy Medical, Inc.
COCH
LISTED
NASDAQ
Envoy Medical Marks Three-Year Anniversary of First Patient Receiving Its Breakthrough Fully Implanted Cochlear Implant
News Preview
The Company looks to build on its recent momentum - receiving FDA approval to expand its pivotal clinical trial into the second and final stageWhite Bear Lake, Minnesota--(Newsfile Corp. - October 29, 2025) - Envoy Medical, Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions,...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2025
ISIN: US70465T1079
PDS Biotechnology Corp
PDSB
LISTED
NASDAQ
PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer
News Preview
Company aims to shorten time frame to make PDS0101 available to patients with HPV16-positive head and neck cancer, projected to be the most dominant type of head and neck cancer in the US by mid 2030s...
Themefolio
Profiler
Peergroup
© EQS Newswire
29.10.2025
ISIN: CA68237C1059
Onco-Innovations Limited
ONCO
LISTED
CSE
Onco-Innovations schreitet mit präklinischem Programm fort
News Preview
EQS-Media / 29.10.2025 / 12:34 CET/CEST
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass das Auftragsforschungsinstitut Nucro-Technics Inc. mit Sitz in Toronto, das in Zusammenarbeit mit Onco präklinische und analytische Entwicklungsdienste durchführt, mit Laborarbeiten im R......
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2025
ISIN: US0044685008
Achieve Life Sciences, Inc.
ACHV
LISTED
NASDAQ
Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 6, 2025
News Preview
SEATTLE and VANCOUVER, British Columbia, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced it will report its third quarter...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2025
ISIN: US75901B1070
Regenxbio Inc
RGNX
LISTED
NASDAQ
REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights
News Preview
ROCKVILLE, Md., Oct. 29, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, November 6, at 8:00 a.m. ET to discuss its financial results for the third quarter ended September 30, 2025, and operational highlights.
Listeners can regist...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2025
ISIN: CH1384053976
NLS Pharmaceutics AG
NLSP
LISTED
NASDAQ
NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger
News Preview
ZURICH, Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for central nervous system and neurodegenerative disorders, and Kadimastem Ltd. (TASE: KDST) ("Kadimastem"), a clinical-stage cell therapy co...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2025
ISIN: BE0003739530
UCB SA
UCB
LISTED
EURONEXT
UCB to unveil new data for RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session
News Preview
UCB will showcase 18 abstracts, including an oral presentation, demonstrating continued commitment to advancing targeted treatments for generalized myasthenia gravis (gMG).
Presentations include new post hoc analyses considering corticosteroid dose tapering during treatment with RYSTIGGO® (rozan...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2025
ISIN: US52490G1022
Legend Biotech Corp
LEGN
LISTED
NASDAQ
Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results
News Preview
SOMERSET, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Wednesday, November 12, 2025, to review third quarter 2025 results....
Themefolio
Profiler
Peergroup
© BusinessWire
29.10.2025
ISIN: US4622221004
Ionis Pharmaceuticals Inc
IONS
LISTED
NASDAQ
Ionis reports third quarter 2025 financial results and highlights progress on key programs
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the third quarter ended September 30, 2025.
"The third quarter was a watershed moment for Ionis, as we made important progress advancing our Ionis-owned medicines. With two independent launches now underway, and two more antic...
Themefolio
Profiler
Peergroup
© BusinessWire
29.10.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LEAP-012 trial evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, plus LENVIMA® (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, in combination with trans...
Themefolio
Profiler
Peergroup
© BusinessWire
29.10.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
European Commission Approves KEYTRUDA® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, as monotherapy for the treatment of resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC) as neoadjuvant treatment, continued as adjuvan...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2025
ISIN: US1266501006
CVS Health Corp
CVS
LISTED
NYSE
CVS HEALTH CORPORATION REPORTS THIRD QUARTER 2025 RESULTS AND UPDATES FULL-YEAR 2025 GUIDANCE
News Preview
Financial Highlights
Third quarter total revenues increased to a record high $102.9 billion, up 7.8% compared to prior year
Third quarter GAAP diluted loss per share of $3.13, inclusive of a $5.7 billion goodwill impairment charge related to th...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2025
ISIN: CA58471K2020
Medicus Pharma Ltd.
MDCX
LISTED
TSX
Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome
News Preview
Gorlin Syndrome, also known as Nevoid Basal Cell Carcinoma Syndrome, is a rare inherited genetic disorder affecting 1 in 31,000 people worldwide that can develop 500-1000 Basal Cell Carcinoma (BCC) lesions over lifetime Gorlin Syndrome, also known as Nevoid Basal Cell Carcinoma Syndrome, is a rare inherited genetic disorder affecting 1 in 31,000 pe...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2025
ISIN: CA92767B1058
Vireo Growth Inc
VREO
LISTED
CSE
Vireo Growth Inc. and Verano Holdings Corp. Announce Resolution of Litigation Matters
News Preview
CHICAGO and MINNEAPOLIS, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (“Vireo”) (CSE: VREO; OTCQX: VREOF) and Verano Holdings Corp. (“Verano”, Vireo and Verano, each a “Company”) (Cboe CA: VRNO) (OTCQX: VRNOF) today announced that they have reached a comprehensive settlement (the “Settlement Agreement”) dismissing all outstanding litigatio...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2025
ISIN: US68554V1089
OraSure Technologies Inc
OSUR
LISTED
NASDAQ
OraSure to Announce Third Quarter 2025 Financial Results and Host Earnings Call on November 5th
News Preview
BETHLEHEM, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering third quarter 2025 financial results and certain business developments for 5 p.m. ET on November 5, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2025
ISIN: US00461U1051
Aclaris Therapeutics Inc
ACRS
LISTED
NASDAQ
Aclaris Therapeutics to Participate in Three November Healthcare Conferences
News Preview
Aclaris Therapeutics to Participate in Three November Healthcare Conferences...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2025
ISIN: US0327973006
Anavex Life Sciences Corp
AVXL
LISTED
NASDAQ
Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Control Group
News Preview
ADAS-Cog13 difference −12.78 (P < 0.0001) with oral blarcamesine treatment compared to ADNI control group at Week 144...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2025
ISIN: US4884452065
Zevra Therapeutics Inc
ZVRA
LISTED
NASDAQ
Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference
News Preview
CELEBRATION, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra’s executive leadership team will participate in a fireside discussion at Guggenheim's 2nd Annua...
Themefolio
Profiler
Peergroup
© BusinessWire
29.10.2025
ISIN: US91307C1027
United Therapeutics Corp
UTHR
LISTED
NASDAQ
United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results
News Preview
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced record financial results for the quarter ended September 30, 2025, driven by continued year-over-year revenue growth in key products such as Tyvaso® and Orenitram®. Total revenues in the third quarter of 2025 grew seven percent year-over-year to $799.5 mi...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2025
ISIN: US26745T1016
Dyadic International Inc
DYAI
LISTED
NASDAQ
Dyadic to Report Third Quarter 2025 Financial Results on Wednesday, November 12, 2025
News Preview
Dyadic to Report Third Quarter 2025 Financial Results on
Wednesday, November 12, 2025...
Themefolio
Profiler
Peergroup
© BusinessWire
29.10.2025
ISIN: US36266G1076
GE Healthcare Technologies Inc
GEHC
LISTED
NASDAQ
GE HealthCare reports third quarter 2025 financial results
News Preview
GE HealthCare (Nasdaq: GEHC) today reported financial results for the third quarter ended September 30, 2025.
GE HealthCare President and CEO Peter Arduini said, “We delivered robust orders with growth across all segments in the third quarter. This was led by customer demand for our differentiated solutions and a healthy capital equipment enviro...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2025
ISIN: US05352A1007
Avantor Inc
AVTR
LISTED
NYSE
Avantor® Reports Third Quarter 2025 Results
News Preview
Net sales of $1.62 billion, decrease of 5%
Net loss of $712 million and diluted GAAP loss per share of $1.04, including a non-cash goodwill impairment charge of $785 million
Adjusted EBITDA of $268 million; adjusted EPS of $0.22
Operating cash flow of $207 mil...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2025
ISIN: US15135B1017
Centene Corp
CNC
LISTED
NYSE
CENTENE CORPORATION REPORTS THIRD QUARTER 2025 RESULTS
News Preview
-- GAAP Diluted Loss Per Share of $(13.50); Adjusted Diluted Earnings Per Share of $0.50 --
Adjusted diluted EPS of $0.50 in the third quarter of 2025, including a $0.10
benefit of a low adjusted effective tax rate in the...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2025
ISIN: KYG8807B1068
Theravance Biopharma Inc
TBPH
LISTED
NASDAQ
Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System
News Preview
Ampreloxetine clinical development program to be featured in four presentations at the upcoming International Symposium on The Autonomic Nervous System
Topline results from the ongoing Phase 3 CYPRESS study of ampreloxetine anticipated in Q1 2026...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2025
ISIN: CH1384053976
NLS Pharmaceutics AG
NLSP
LISTED
NASDAQ
NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem
News Preview
ZURICH, Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announc...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Communiqué de presse : Sanofi ancre son futur en France avec un nouveau siège emblématique à Paris La Défense
News Preview
Sanofi ancre son futur en France avec un nouveau siège emblématique à Paris La Défense...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2025
ISIN: US6876041087
Oruka Therapeutics, Inc.
ORKA
LISTED
NASDAQ
Oruka Therapeutics to Present at Multiple November Investor Conferences
News Preview
MENLO PARK, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced presentations at the following upcoming investor conferenc...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2025
ISIN: US30233G2093
EyePoint Pharmaceuticals Inc
EYPT
LISTED
NASDAQ
EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025
News Preview
WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 5, 2...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2025
ISIN: US5147661046
Lifecore Biomedical Inc
LFCR
LISTED
NASDAQ
Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company
News Preview
Lifecore to Execute Commercial Site Transfer and Become New Supplier of Choice for Leading Commercial Injectable Pharmaceutical Product...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2025
ISIN: US05463X1063
AxoGen Inc
AXGN
LISTED
NASDAQ
Axogen, Inc. Reports Third Quarter 2025 Financial Results
News Preview
Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 million Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 million...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2025
ISIN: US3596161097
Fulcrum Therapeutics Inc
FULC
LISTED
NASDAQ
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025
News Preview
― Announced encouraging results in July 2025 from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ―...
Themefolio
Profiler
Peergroup
© BusinessWire
29.10.2025
ISIN: US8835561023
Thermo Fisher Scientific Inc
TMO
LISTED
NYSE
Thermo Fisher Scientific to Acquire Clario Holdings, Inc., Enabling Pharma and Biotech Customers to Accelerate Innovation with Deeper Clinical Insights
News Preview
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced a definitive agreement to acquire Clario Holdings, Inc., a leading provider of endpoint data solutions for clinical trials, from a shareholder group led by Astorg and Nordic Capital, Novo Holding and Cinven, for $8.875 billion in cash at close plus pote...
Themefolio
Profiler
Peergroup
© BusinessWire
29.10.2025
ISIN: CA68617J1003
Organigram Global Inc
OGI
LISTED
NASDAQ
Majority of Canadians Want Carney Government to Catch Up on Cannabis Policy
News Preview
Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), Canada’s largest cannabis company by market share, today released new national polling figures, conducted on its behalf by Abacus Data showing that a clear majority of Canadians want Ottawa to modernize its approach to the legal cannabis sector.
Nearly six in ten Canadians (59%) believe the federa...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2025
ISIN: US5019761049
Kyverna Therapeutics, Inc.
KYTX
LISTED
NASDAQ
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025
News Preview
Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company’s registrational KYSA-6 Phase 3 MG trial...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2025
ISIN: CA64119M1059
Netramark Holdings Inc
AIAI
LISTED
CSE
NetraMark Presents AI-Driven Advances in Precision Psychiatry to Enhance Clinical Trial Designs at Joint Autumn Conference
News Preview
TORONTO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, presented two significant applications of its technolo...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
